Breaking Down SG&A Expenses: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampBioCryst Pharmaceuticals, Inc.Pharming Group N.V.
Wednesday, January 1, 201474610004042025
Thursday, January 1, 2015130470005279557
Friday, January 1, 2016112530008073913
Sunday, January 1, 20171393300044864073
Monday, January 1, 20182951400053488904
Tuesday, January 1, 20193712100065896361
Wednesday, January 1, 20206792900069968267
Friday, January 1, 202111881800092047281
Saturday, January 1, 2022159371000131819000
Sunday, January 1, 202321389400087501000
Loading chart...

Unlocking the unknown

A Comparative Analysis of SG&A Expenses in the Biotech Sector

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Pharming Group N.V. and BioCryst Pharmaceuticals, Inc., from 2014 to 2023.

BioCryst Pharmaceuticals has shown a remarkable increase in SG&A expenses, growing by approximately 2,800% over the decade. This surge reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Pharming Group N.V. experienced a more moderate increase of around 2,100%, indicating a steady yet strategic growth approach.

The year 2022 marked a peak for both companies, with BioCryst's expenses reaching their highest at 159 million, while Pharming Group's expenses peaked at 132 million. These trends highlight the evolving strategies and market positioning of these biotech giants, offering valuable insights for industry observers.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025